Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.